Tag

Euan gained a first class honours in Molecular Biology followed by a PhD in Medical Genetics from the University of Aberdeen.

In 2000 he joined Prof Hani Gabra and his team at the, then Imperial Cancer Research Fund now Cancer Research UK, unit in Edinburgh as a postdoctoral fellow.

From there he moved to Imperial College in 2003 where he ran the Molecular Therapy Lab within the Ovarian Cancer Action Research Centre. 

Since 2015 he is a Senior Investigator at GlaxoSmithKline.

Eaun is a Honorary Senior Lecturer at Imperial College London.

Dr Ioannis Pandis received a Ph.D. degree in Biological Chemistry from the BSRC “Al. Fleming” Institute in Athens, Greee in 2012.

From 2012, he has been working as a research associate at Imperial College. He is in the Discovery Science Group working on the European Innovatice Medicine Initiative (IMI), eTRIKs project, which is aimed at developing a translational information and knowledge management systems.

His personal interest is the development of bioinformatic applications enabling applied biomedical research, with a particular focus on genome regulation analysis.

Dr Cavallaro is a cell biologist and molecular oncologist interested in the biological mechanisms that underlie cancer development.

With his research group he discovered a novel interaction between the adhesion molecule NCAM and the receptor tyrosine kinase FGFR, introducing the paradigm that a growth factor receptor can be activated by a non-canonical ligand such as an adhesion molecule (Francavilla et al., J Cell Sci, 2007, and J Cell Biol, 2009).

His group also discovered that the NCAM/FGFR interaction plays a causal role in ovarian cancer, where it also emerged as a potential therapeutic target in preclinical models (Zecchini et al., EMBO Mol Med, 2011).

Another adhesion molecule that is intensively studied in his lab is L1, originally described as a neural adhesion molecule. They reported that L1 is expressed in specific lineages of the hematopoietic compartment, where it regulates immune cell motility and trafficking (Maddaluno et al., J Exp Med, 2009). Furthermore, his group reported that L1 plays a dual, cell context-dependent role in ovarian cancer (Zecchini et al, Cancer Res, 2008).

More recently, his research group became interested in the novel, unexpected role of adhesion molecules in tumor angiogenesis and vascular maturation. These observations led them to propose novel therapeutic target for anti-angiogenic treatments.

He is actively addressing these scientific issues in preclinical models and clinical samples of specific tumor types, such as pancreatic and ovarian carcinoma.

Another area of intense research in his group is the identification and characterisation of ovarian cancer stem cells, namely an elusive subset of transformed cells that is is thought to drive cancer development, dissemination, recurrence and chemoresistance.

Finally, they are actively pursuing the definition of novel ovarian cancer biomarkers and potential targets, combining cutting edge technologies with the use of clinically relevant specimens, taking advantage of a close collaboration with IEO gynecological oncologists

Professor Robert Zeillinger is an Associate Professor at the Ludwig Boltzmann Institute for Gynecology and Gynecological Oncology, Department of Obstetrics and Gynecology, University of Vienna.

A graduate in biochemistry, Professor Zeillinger is also the founder and the head of the Molecular Oncology Group at The Department of Obstetrics and Gynaecology at the Medical University of Vienna. The main objectives of the group's research are understanding gynaecological cancers at molecular levels, improving diagnosis and prognosis and defining novel therapeutic targets.

The interdisciplinary group is engaged in various national and international organizations and networks (e.g. TOC – Tumor Bank Ovarian Cancer; EUTROC – European Network for Translational Research in Ovarian Cancer; OCTIPS – Ovarian Cancer Therapy Innovative Models; OVCAD – Ovarian Cancer Diagnosis; Ludwig Boltzmann Gesellschaft – Cluster Translational Oncology).

Yike Guo is a Professor of Computing Science in the Department of Computing at Imperial College London. He leads the Discovery Science Group in the department, as well as being the founding Director of the Data Science Institute at Imperial College.

Professor Guo also holds the position of CTO of the tranSMART Foundation, a global open source community using and developing data sharing and analytics technology for translational medicine.

Professor Guo received a first-class honours degree in Computing Science from Tsinghua University, China, in 1985 and received his PhD in Computational Logic from Imperial College in 1993 under the supervision of Professor John Darlington.

He founded InforSense, a healthcare intelligence company, and served as CEO for several years before the company's merger with IDBS, a global advanced R&D software provider, in 2009. He has been working on technology and platforms for scientific data analysis since the mid-1990s, where his research focuses on knowledge discovery, data mining and large-scale data management.

He has contributed to numerous major research projects including: the UK EPSRC platform project, Discovery Net; the Wellcome Trust-funded Biological Atlas of Insulin Resistance (BAIR); and the European Commission U-BIOPRED project. He is currently the Principal Investigator of the European Innovative Medicines Initiative (IMI) eTRIKS project, a €23M project that is building a cloud-based informatics platform, in which tranSMART is a core component for clinico-genomic medical research, and co-Investigator of Digital City Exchange, a £5.9M research programme exploring ways to digitally link utilities and services within smart cities.

Professor Guo has published over 200 articles, papers and reports. Projects he has contributed to have been internationally recognised, including winning the “Most Innovative Data Intensive Application Award” at the Supercomputing 2002 conference for Discovery Net, and the Bio-IT World "Best Practices Award" for U-BIOPRED in 2014. He is a Senior Member of the IEEE and is a Fellow of the British Computer Society.